RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention

Launched by RAK MEDICAL AND HEALTH SCIENCES UNIVERSITY · Mar 3, 2025

Keywords

ClinConnect Summary

The RAK-PRIDE trial is studying whether a special education program led by pharmacists can help reduce the unnecessary use of proton pump inhibitors (PPIs) among adults. PPIs are medications often used to treat heartburn and acid reflux, but sometimes they are prescribed when they may not be needed. The researchers want to find out if providing patients and their doctors with helpful information can lower the number of people taking these medications without a good reason, improve patients' quality of life, and save on healthcare costs.

To participate in this study, you must be at least 18 years old and have a prescription for a PPI that might not be appropriate. Doctors who prescribe these medications in the outpatient departments of the study sites can also join if they are treating patients with potentially unnecessary PPI prescriptions. As a participant, you will receive educational materials from pharmacists, such as brochures and action plans, and your doctor will get support too. The study will follow up with you for six months to see how your medication use and overall health change. This trial is currently looking for participants, and your involvement could help improve healthcare for many others facing similar issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Physicians will be eligible to participate if:
• • They are prescribing PPIs in outpatient department of the study sites
• • They have patients with potentially inappropriate PPI prescriptions
• Patients will be eligible to participate if:
• • They are ≥18 years
• • They are presenting to out-patient departments of the study sites
• • They have prescriptions of potentially inappropriate PPIs
• • Their treating physicians are included in the study
• Exclusion Criteria:
• Physicians will be excluded if:
• • • They are involved in any other prescribing trial
• Patients will be excluded if:
• • They are unable to give informed consent, as judged by their physicians
• • They have definitive indications for PPI use